Funmi Adewale's Archive

info@myelomabeacon.com

 Funmi Adewale graduated from Cornell University in January 2010 with a BS in Biological Sciences. She plans to pursue a graduate degree in the near future, and her long-term goal is to further the communication of scientific knowledge to non-scientists. Funmi joined The Myeloma Beacon team in November 2009. Raised in Pittsburgh, Pennsylvania, she currently lives near Charlotte, North Carolina. Her interests include music, writing, languages, and sleep.

Funmi Adewale has written 31 article(s).

Revlimid Maintenance Therapy Is Added To Multiple Myeloma Treatment Guidelines
[ by Funmi Adewale | Feb 12, 2010 2:04 pm | One Comment ]
Revlimid Maintenance Therapy Is Added To Multiple Myeloma Treatment Guidelines

In its latest version of guidelines for multiple myeloma treatment, the National Comprehensive Cancer Network (NCCN) recommended the use of Revlimid (lenalidomide) as a maintenance therapy after stem cell transplantation. The NCCN based their decision on the preliminary findings of three Phase 3 trials: MM-015, CALGB 100104, and IFM 2005-02.

“[Revlimid] as maintenance has been evaluated in three independent randomized clinical trials. Results from each of these trials show improvements in time-to-progression,” the NCCN myeloma guidelines state. “The panel…

Read the full story »
Vertebroplasty Relieves Pain And Restores Mobility In Myeloma-Related Spinal Fractures, Study Finds
[ by Funmi Adewale | Feb 10, 2010 9:46 am | 2 Comments ]
Vertebroplasty Relieves Pain And Restores Mobility In Myeloma-Related Spinal Fractures, Study Finds

A recent study published in the journal Neurological Sciences determined that injecting bone cement into fracture sites in the spine, a procedure called vertebroplasty, leads to fast pain relief and restored mobility in multiple myeloma patients.

Myeloma cells accelerate processes that degrade bone, resulting in bone lesions and fractures. Spinal fractures, in particular, are a common complication associated with multiple myeloma and can leave patients unable to walk. Treatment options include radiation therapy, medication, and a minimally invasive procedure called…

Read the full story »
Beacon NewsFlashes – February 5, 2010
[ by Funmi Adewale | Feb 5, 2010 1:03 pm | No Comments ]
Beacon NewsFlashes – February 5, 2010

LLS Increases Financial Support For Myeloma Patients – As of Feb 1, the Leukemia & Lymphoma Society (LLS) will provide multiple myeloma patients with up to $10,000 to cover insurance-related expenses such as co-payments and insurance premiums. The new limit is an increase from the previous limit of $5,000 and is retroactive for expenses beginning July 1, 2009. For more information or to apply, please see the LLS Co-Pay Assistance Web site.

Carfilzomib Phase 3 Clinical Trial Design Is…

Read the full story »
Defibrotide
[ by Funmi Adewale | Feb 4, 2010 1:18 pm | No Comments ]
Brand Name:  
Generic Name: defibrotide
Code Name:  
Company: Gentium SpA
FDA Clinical Phase: 1/2

Description:
Defibrotide is an anticoagulant (a drug that prevents blood clotting) that may make myeloma cells more susceptible to chemotherapy. It is not an anti-tumor drug and only has a significant effect on myeloma when combined with cancer-fighting drugs.  Defibrotide may decrease blood clotting and nerve damage…

Read the full story »
Page 4 of 8« First...«23456»...Last »